These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 3302713)

  • 1. Payment restrictions for prescription drugs under Medicaid. Effects on therapy, cost, and equity.
    Soumerai SB; Avorn J; Ross-Degnan D; Gortmaker S
    N Engl J Med; 1987 Aug; 317(9):550-6. PubMed ID: 3302713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes.
    Soumerai SB; Ross-Degnan D; Avorn J; McLaughlin Tj; Choodnovskiy I
    N Engl J Med; 1991 Oct; 325(15):1072-7. PubMed ID: 1891009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences in the cost of antidepressants across state Medicaid programs.
    Kelton CM; Rebelein RP; Heaton PC; Ferrand Y; Guo JJ
    J Ment Health Policy Econ; 2008 Mar; 11(1):33-47. PubMed ID: 18424875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing the effect of Taiwan's outpatient prescription drug copayment policy in the elderly.
    Liu SZ; Romeis JC
    Med Care; 2003 Dec; 41(12):1331-42. PubMed ID: 14668666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unintended outcomes of medicaid drug cost-containment policies on the chronically mentally ill.
    Soumerai S
    J Clin Psychiatry; 2003; 64 Suppl 17():19-22. PubMed ID: 14680423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of copayments on drug use in the presence of annual payment limits.
    Kephart G; Skedgel C; Sketris I; Grootendorst P; Hoar J
    Am J Manag Care; 2007 Jun; 13(6 Pt 2):328-34. PubMed ID: 17567233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Out-of-pocket health spending by poor and near-poor elderly Medicare beneficiaries.
    Gross DJ; Alecxih L; Gibson MJ; Corea J; Caplan C; Brangan N
    Health Serv Res; 1999 Apr; 34(1 Pt 2):241-54. PubMed ID: 10199672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trends in prescription drug expenditures by Medicaid enrollees.
    Banthin JS; Miller GE
    Med Care; 2006 May; 44(5 Suppl):I27-35. PubMed ID: 16625061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Washington State CARE Project: downstream cost changes associated with the provision of cognitive services by pharmacists.
    Smith DH; Fassett WE; Christensen DB
    J Am Pharm Assoc (Wash); 1999; 39(5):650-7. PubMed ID: 10533346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outpatient prescription drug utilization and expenditure patterns of noninstitutionalized aged Medicare beneficiaries.
    LaVange LM; Silverman HA
    Natl Med Care Util Expend Surv B; 1987 Apr; (12):1-43. PubMed ID: 10313516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Consumer response to dual incentives under multitiered prescription drug formularies.
    Gilman BH; Kautter J
    Am J Manag Care; 2007 Jun; 13(6 Pt 2):353-9. PubMed ID: 17567236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How does Cash and Counseling affect costs?
    Dale SB; Brown RS
    Health Serv Res; 2007 Feb; 42(1 Pt 2):488-509. PubMed ID: 17244294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Copayment for pharmaceutical services in a Medicaid program.
    Nelson AA; Quick MR
    Contemp Pharm Pract; 1980; 3(1):37-42. PubMed ID: 10297666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential savings from increased use of generic drugs in the elderly: what the experience of Medicaid and other insurance programs means for a Medicare drug benefit.
    Fischer MA; Avorn J
    Pharmacoepidemiol Drug Saf; 2004 Apr; 13(4):207-14. PubMed ID: 15255087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medicare: looking for pareto optimal changes.
    Christensen S
    Inquiry; 1992; 29(4):426-39. PubMed ID: 1473866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of a Medicaid copayment policy on prescription drug and health services utilization in a fee-for-service Medicaid population.
    Hartung DM; Carlson MJ; Kraemer DF; Haxby DG; Ketchum KL; Greenlick MR
    Med Care; 2008 Jun; 46(6):565-72. PubMed ID: 18520310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cluster analysis of state Medicaid prescription drug benefit programs based on potential determinants of per capita drug expenditure.
    Roy S; Madhavan SS
    Res Social Adm Pharm; 2009 Mar; 5(1):51-62. PubMed ID: 19285289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors.
    Fischer MA; Schneeweiss S; Avorn J; Solomon DH
    N Engl J Med; 2004 Nov; 351(21):2187-94. PubMed ID: 15548779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of mail-service and retail community pharmacy claims in 5 prescription benefit plans.
    Clark BE; Siracuse MV; Garis RI
    Res Social Adm Pharm; 2009 Jun; 5(2):133-42. PubMed ID: 19524861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medicaid prescription cost containment and schizophrenia: a retrospective examination.
    Farley JF
    Med Care; 2010 May; 48(5):440-7. PubMed ID: 20351586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.